Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
Breast cancer survival in Nordic BRCA2 mutation carriers-unconventional association with oestrogen receptor status.
复制标题
DOI：
10.1038/s41416-020-01056-4
复制
发表时间：
2020-11
影响因子：
8.8
通讯作者：
Tryggvadottir L
中科院分区：
文献类型：
--
作者：
Olafsdottir EJ;Borg A;Jensen MB;Gerdes AM;Johansson ALV;Barkardottir RB;Johannsson OT;Ejlertsen B;Sønderstrup IMH;Hovig E;Lænkholm AV;Hansen TVO;Olafsdottir GH;Rossing M;Jonasson JG;Sigurdsson S;Loman N;Nilsson MP;Narod SA;Tryggvadottir L
BRCA2携带者患乳腺癌的自然病史尚未明确。在冰岛之前的一项研究中，ER阳性状态是一个负面的预后因素。我们试图在扩大的BRCA2携带者队列中确定预测浸润性乳腺癌后生存率的因素。我们研究了来自四个北欧国家的608名患有浸润性乳腺癌和致病BRCA2突变(变异)的妇女。从健康记录和分析存档的组织标本中检索有关预后因素和治疗的信息。通过COX回归估计乳腺癌特异性生存的风险比(HR)。约77%的癌症ER阳性，其中40岁以下患者的比例最高(83%)。ER阳性乳腺癌更有可能是淋巴结阳性(59%)而不是ER阴性乳腺癌(34%)(P <； 0.001)。生存分析包括584例患者。ER阳性在发病后前5年有保护作用(多变量HR = 为0.49；95%CI为0.2 6~0.93，P = 0.0 3)，此后为不良反应(HR = 为1.91；95%CI为1.0 7~3.39，P = 为0.0 3)。ER阳性的不良反应仅限于未接受内分泌治疗的妇女(HR = 2.36；95%CI 1.2 6~4.44，P = 0.0 1)和卵巢完整的患者(HR = 1.99；95%CI 1.11~3.5 9，P = 0.0 2)。乳腺癌BRCA2携带者雌激素受体状态阳性的不良反应可能取决于卵巢激素的暴露。
The natural history of breast cancer among BRCA2 carriers has not been clearly established. In a previous study from Iceland, positive ER status was a negative prognostic factor. We sought to identify factors that predicted survival after invasive breast cancer in an expanded cohort of BRCA2 carriers. We studied 608 women with invasive breast cancer and a pathogenic BRCA2 mutation (variant) from four Nordic countries. Information on prognostic factors and treatment was retrieved from health records and by analysis of archived tissue specimens. Hazard ratios (HR) were estimated for breast cancer-specific survival using Cox regression. About 77% of cancers were ER-positive, with the highest proportion (83%) in patients under 40 years. ER-positive breast cancers were more likely to be node-positive (59%) than ER-negative cancers (34%) (P < 0.001). The survival analysis included 584 patients. Positive ER status was protective in the first 5 years from diagnosis (multivariate HR = 0.49; 95% CI 0.26–0.93, P = 0.03); thereafter, the effect was adverse (HR = 1.91; 95% CI 1.07–3.39, P = 0.03). The adverse effect of positive ER status was limited to women who did not undergo endocrine treatment (HR = 2.36; 95% CI 1.26–4.44, P = 0.01) and patients with intact ovaries (HR = 1.99; 95% CI 1.11–3.59, P = 0.02). The adverse effect of a positive ER status in BRCA2 carriers with breast cancer may be contingent on exposure to ovarian hormones.
登录
查看更多内容
影响因子：
6.4
作者：
Johansson, Anna L. V.;Trewin, Cassia B.;Ursin, Giske
通讯作者：
Ursin, Giske
影响因子：
10.3
作者：
Heemskerk-Gerritsen, B. A. M.;Seynaeve, C.;Hooning, M. J.
通讯作者：
Hooning, M. J.
影响因子：
3.8
作者：
Sopik, Victoria;Sun, Ping;Narod, Steven A.
通讯作者：
Narod, Steven A.
影响因子：
11.5
作者：
Foulkes, WD;Metcalfe, K;Narod, SA
通讯作者：
Narod, SA
影响因子：
3.8
作者：
Nilsson, Martin P.;Torngren, Therese;Loman, Niklas
通讯作者：
Loman, Niklas